Receptor desensitization and blockade of the suppressive effects of prostaglandin E2and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 111-122

  Su, Yunyun ^a   Jackson, Edwin K ^b   Gorelik, Elieser ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Human CTLs; PGE2; Tumor immunology

Indexed keywords

2 CHLOROADENOSINE; ADENOSINE A2 RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; T LYMPHOCYTE RECEPTOR;

ARTICLE; CANCER RESISTANCE; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MELANOMA; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; T LYMPHOCYTE;

ADENOSINE; ALPROSTADIL; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DINOPROSTONE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; PHENETHYLAMINES; RECEPTOR CROSS-TALK; RECEPTOR, ADENOSINE A2A; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 79953764331     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0924-z     Document Type: Article

References (44)

1. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240
2. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915 (Pubitemid 39273730)
3. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-1544
4. Gabrilovich DI (2007) Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Curr Cancer Drug Targets 7:1
5. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213:131-145 (Pubitemid 44401498)
6. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118-1122
7. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8 + T cells in patients with melanoma. J Immunol 175:6169-6176 (Pubitemid 41508105)
8. Cronstein BN (1994) Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76:5-13
9. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP (2002) Prostaglandins as modulators of immunity. Trends Immunol 23:144-150 (Pubitemid 34178297)
10. Hasko G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33-39 (Pubitemid 38032805)
11. Hata AN, Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103:147-166 (Pubitemid 39209041)
12. 2A receptors. Annu Rev Immunol 22:657-682
13. Sitkovsky MV, Ohta A (2005) The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol 26:299-304
14. 2A signaling. Prog Neurobiol 83:263-276
15. Kundu N, Walser TC, Ma X, Fulton AM (2005) Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 54:981-987 (Pubitemid 41187706)
16. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E (2005) Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 175:4383-4391 (Pubitemid 41361973)
17. Su Y, Huang X, Raskovalova T, Zacharia L, Lokshin A, Jackson E, Gorelik E (2008) Cooperation of adenosine and prostaglandin E(2) (PGE (2)) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 57:1611-1623
18. Blay J, White TD, Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602-2605 (Pubitemid 27283766)
19. Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclo-oxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4:431-436 (Pubitemid 38050040)
20. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 103:13132-13137 (Pubitemid 44338928)
21. 2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem 272:25881-25889
22. Raskovalova T, Lokshin A, Huang X, Su Y, Mandic M, Zarour HM, Jackson EK, Gorelik E (2007) Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8 + and CD4 + T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res 67:5949-5956 (Pubitemid 46985031)
23. 2A-receptor-gene-deficient mice. Biochem J 354:123-130
24. Desai S, April H, Nwaneshiudu C, Ashby B (2000) Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. Mol Pharmacol 58:1279-1286
25. Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24
26. Klaasse EC, Ijzerman AP, de Grip WJ, Beukers MW (2008) Internalization and desensitization of adenosine receptors. Purinergic Signal 4:21-37
27. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520 (Pubitemid 44394910)
28. Schmedt C, Saijo K, Niidome T, Kuhn R, Aizawa S, Tarakhovsky A (1998) Csk controls antigen receptor-mediated development and selection of T-lineage cells. Nature 394:901-904 (Pubitemid 28410913)
29. Tasken K, Ruppelt A (2006) Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts. Front Biosci 11:2929-2939 (Pubitemid 43800386)
30. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Horejsi V, Schraven B, Rolstad B, Mustelin T, Tasken K (2001) Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J Biol Chem 276:29313-29318
31. Vang T, Abrahamsen H, Myklebust S, Enserink J, Prydz H, Mustelin T, Amarzguioui M, Tasken K (2004) Knockdown of C-terminal Src kinase by siRNA-mediated RNA interference augments T cell receptor signaling in mature T cells. Eur J Immunol 34:2191-2199 (Pubitemid 39256100)
32. Vang T, Abrahamsen H, Myklebust S, Horejsi V, Tasken K (2003) Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase A inhibits T cell receptor signaling. J Biol Chem 278:17597-17600 (Pubitemid 36799360)
33. Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. Annu Rev Immunol 27:591-619
34. Fuller CL, Ravichandran KS, Braciale VL (1999) Phosphatidylinositol 3-kinase-dependent and -independent cytolytic effector functions. J Immunol 162:6337-6340 (Pubitemid 29309352)
35. Okkenhaug K, Vanhaesebroeck B (2003) PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3:317-330 (Pubitemid 37328684)
36. Sugiyama H, Chen P, Hunter M, Taffs R, Sitkovsky M (1992) The dual role of the cAMP-dependent protein kinase C alpha subunit in T-cell receptor-triggered T-lymphocytes effector functions. J Biol Chem 267:25256-25263
37. Takayama H, Trenn G, Sitkovsky MV (1988) Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway. J Biol Chem 263:2330-2336 (Pubitemid 18060293)
38. Torgersen KM, Vaage JT, Levy FO, Hansson V, Rolstad B, Tasken K (1997) Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J Biol Chem 272:5495-5500 (Pubitemid 27102370)
39. Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skalhegg BS, Hansson V, Mustelin T, Tasken K (2001) Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193:497-507 (Pubitemid 32524480)
40. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF (2006) Modulation by IL-2 of CD70 and CD27 expression on CD8 + T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176:7726-7735 (Pubitemid 43849073)
41. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27 + CD28 + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105:241-250 (Pubitemid 40053089)
42. 2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 153(Suppl 1):457-464
43. Ohta A, Kjaergaard J, Sharma S, Mohsin M, Goel N, Madasu M, Fradkov E, Sitkovsky M (2009) In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. Br J Pharmacol 156:297-306
44. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854 (Pubitemid 35231542)